# Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

> **NCT07130032** · PHASE2 · RECRUITING · sponsor: **EuroCityClinic LLC** · enrollment: 90 (estimated)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer (NSCLC)
- Metastatic Cutaneous Melanoma

## Interventions

- **COMBINATION_PRODUCT:** reICB regimen (NSCLC)
- **COMBINATION_PRODUCT:** reICB regimen (melanoma)

## Key facts

- **NCT ID:** NCT07130032
- **Lead sponsor:** EuroCityClinic LLC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-14
- **Primary completion:** 2025-08-14
- **Final completion:** 2027-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130032, "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07130032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*